Anne Rogiers
cris.vub.be
0000-0003-3716-2559
Vrije Universiteit Brussel
32 papers found
Refreshing results…
Emotional Distress, Cognitive Complaints, and Care Needs among Advanced Cancer Survivors Treated with Immune Checkpoint Blockade: A Mixed-Method Study
1860P Objective and subjective neurocognitive functioning (NCF) in advanced cancer survivors treated with immune checkpoint blockade (ICB)
Objective and subjective neurocognitive functioning (NCF) in advanced cancer survivors treated with immune checkpoint blockade (ICB)
Real-World Effectiveness, Safety, and Health-Related Quality of Life in Patients Receiving Adjuvant Nivolumab for Melanoma in Belgium and Luxembourg: Results of PRESERV MEL
Health-state utilities in long-term advanced melanoma survivors comparable with the general population
Neurocognitive Functioning in Metastatic Cancer Survivors Treated With Immune Checkpoint Blockade: First Results of A Single Center Cohort Study
Cancer-related cognitive impairment in non-CNS cancer patients: Targeted review and future action plans in Europe
Patient-reported outcomes for monitoring symptomatic toxicities in cancer patients treated with immune-checkpoint inhibitors: A Delphi study
1686P Selecting patient-reported outcomes to monitor symptomatic toxicities of immune-checkpoint inhibitors: A Delphi study
A Comprehensive Analysis of Baseline Clinical Characteristics and Biomarkers Associated with Outcome in Advanced Melanoma Patients Treated with Pembrolizumab
Axitinib plus avelumab in the treatment of recurrent glioblastoma: a stratified, open-label, single-center phase 2 clinical trial (GliAvAx)
Health-related quality of life of long-term advanced melanoma survivors treated with anti-CTLA-4 immune checkpoint inhibition compared to matched controls
Neurocognitive Function, Psychosocial Outcome, and Health-Related Quality of Life of the First-Generation Metastatic Melanoma Survivors Treated with Ipilimumab
A phase I clinical trial on intratumoral and intracavitary administration of ipilimumab and nivolumab in patients with recurrent glioblastoma.
Health-related quality of life, psychological outcome and neurocognitive function in metastatic melanoma survivors treated with immune checkpoint inhibitors
Health related quality of life, psycho-social outcome and neurocognitive function in metastatic melanoma survivors treated with immune checkpoint inhibitors
Health-related quality of life, emotional burden, and neurocognitive function in the first generation of metastatic melanoma survivors treated with pembrolizumab: a longitudinal pilot study
Glitipni: A Phase 1b Clinical Trial Combining Surgical Resection With Direct Intracerebral Injection of Immune Checkpoint Inhibitors in Patients With Recurrent Glioblastoma
GLIAVAX: A stratified phase II clinical trial of avelumab and axitinib in patients with recurrent glioblastoma.
Long-Term Survival, Quality of Life, and Psychosocial Outcomes in Advanced Melanoma Patients Treated with Immune Checkpoint Inhibitors
Missing publications? Search for publications with a matching author name.